	Day 1: September 24, 2018		
8:30 a.m.	Program Registration		
9:00 - 9:30	Welcome & Overview Ice-Breaker/Self-introductions	Kathleen Boozang, Seton Hall Law School (New Jersey) Ela Bochenek, Seton Hall Law School (New Jersey)	
9:30 – 10:30	Ethics as a Foundation for Corporate Compliance Programs (A look at why business ethics is an important part of compliance and a company's culture)	Kathleen Boozang, Seton Hall Law School (New Jersey)	
10:30 - 10:50	Break		
10:50 – 12:10	Overview of the key data protection risks facing multinationals; the complex regulatory landscape for privacy and data protection in LATAM & globally)	Erick de Jesús Pérez Patiño, Alcon (Mexico) Dirceu Santa Rosa, Montaury Pimenta, Machado & Vieira de Mello (Rio de Janeiro)	
12:10 - 1:10	Lunch		
1:10 – 2:40	Building a Compliance Team & Creating a Culture of Compliance (An examination of ways to recruit, develop, and promote a team of compliance professionals; interactive exercise describing methods that companies can use with employees to help build an ethical business culture)	Cory LaBarge, Grünenthal Group (Panama) Michael Mayes, Astellas (Illinois)	
2:40 – 4:10	Assessing Third Party Risk (Best practices on how to conduct tiered due diligence and implement internal controls to mitigate the risks associated with third parties)	Antonio Caram, Johnson & Johnson (Miami) Ariadna Quesada, AbbVie Inc. (Netherlands)	
4:10 - 4:30	Break		
4:30 – 5:30	Monitoring Programs (Monitoring, auditing, and how to improve upon these programs within your companies)	Sergio Alberto Pinto, Johnson & Johnson (São Paulo)	

8:45 a.m.	Day 2: September 25, 2018		
	Sign-In		
9:00 – 9:15	Day 1 Overview	Kathleen Boozang, Seton Hall Law School (New Jersey)	
9:15 – 10:30	Drug & Device Development & Approval Process (A comprehensive overview of the laws/regulations and key requirements involved in the new drug and device approval process, including classifying and testing new products, the application process, and the various pathways to marketing a product)	Patricia Fukuma, Fukuma Advogados & Consultores (São Paulo) Martiza Moncayo, IRIS GLOBAL (Chicago)	
10:30 - 10:45	Break		
10:45 – 11:40	Transparency & Disclosure Reporting (An overview of the disclosure reporting requirements for transfers of value to health care professionals; what are the risks and what have we learned from other regions)	Diva Duong, IQVIA (Paris)	
11:40 – 1:00	Advertising & Promotion of Drugs & Medical Devices (A discussion of the key requirements and regulations for advertising and promoting prescription drugs and medical devices, special risk areas for pre-launch activities, and social media)	Angela Kung, Pinheiro Neto (São Paulo) Ignacio Gillmore, Carey Law Firm (Santiago) Adrián del Paso, Ibarra, del Paso, y Gallego, S.C. (Mexico City) <i>Moderator:</i> Felipe Kietzmann, former ABIMED Chairman (São Paulo)	
1:00 - 2:00	Lunch		
2:00 – 3:30	Industry Interactions with Patient Organizations/Judicialization of Health in Brazil (Discussion of the types of industry interactions with patients and patient organizations and how to identify and manage the ethical issues and potential conflicts of interest that may arise)	Marcos Lobo de Freitas Levy, A. Lopes Muniz (São Paulo)	
3:30 – 4:30	The Future of Compliance	Michael Mayes, Astellas (Illinois)	
4:30 - 4:45	Break		
4:45 – 5:45	Compliance Officers' Panel Discussion	Sergio Abreu, Merck (Uruguay) Cory LaBarge, Grünenthal Group (Panama) Michael Mayes, Astellas (Illinois) Marcelo Nogueira, Novartis (São Paulo) Moderator: Richard Sobkiewicz, Norton Rose Fulbright (Rio de Janeiro)	
5:45 – 7:30	Networking Reception for All Program Faculty & Attendees at Living Lounge Bar & Sushi, Hotel Lobby - sponsored by EY		

	Day 3: September 26, 2018	
8:45 a.m.	Sign-In	DEN 20, 2010
9:00 – 10:15	Anti-Corruption Risks & Enforcement in LATAM Markets (Key risk areas for the life sciences industry, including with respect to third parties, global anti-corruption laws, industry trends, and lessons learned from other high-risk markets)	Vanina Caniza, Baker McKenzie (Buenos Aires) Henrique Frizzo, Trench Rossi Watanabe (São Paulo) Gregory Paw, Pepper Hamilton LLP (Philadelphia)
10:15 - 10:35	Break	
10:35 – 12:05	FCPA/UK Bribery Act (A session focusing on the Foreign Corruption Practices Act, the UK Bribery Act, and global anti-corruption enforcement)	Gary Giampetruzzi, Paul Hastings (New York) Jonathan Stevens, Paul Hastings (California)
12:05 – 1:05	Lunch	
1:05 – 2:20	Conducting an Internal Investigation (An examination of what conduct triggers the need for an internal investigation, who should be involved, and how to handle the results)	Gildas Durand, E&Y (Miami) Diana Borges, Merz Americas (North Carolina)
2:20 – 3:35	Enforcement Landscape in Brazil (The risks associated with third parties and importance of conducting due diligence within the Brazilian market)	Benny Spiewak, SPLAW Advogados (São Paulo)
3:35 – 3:55	Break	
3:55 – 5:15	Group Exercise	Kathleen Boozang, Seton Hall Law School (New Jersey)

	Day 4: September 27, 2018	
8:45 a.m.	Sign-In	
9:00 – 10:00	Country Review Session – Argentina, Peru, Chile	Pedro Serrano Espelta, Marval, O'Farrell & Mairal (Buenos Aires)
10:00 – 10:20	Break	
10:20 – 11:05	Culture and Compliance	Ela Bochenek, Seton Hall Law School (New Jersey) Marcos Lobo de Freitas Levy, A. Lopes Muniz (São Paulo)
11:05 – 12:05	Strengthening Compliance Programs Through Data Analytics (A look at what data analytics is and how it can be used to help detect, predict, and prevent future compliance risks)	Toni Hahn, Johnson & Johnson Corporate Internal Audit (New Jersey) Patricia Miguel, E&Y (São Paulo)
12:05 – 1:05	Lunch	
1:05 – 2:05	Building Relationships While Maintaining Compliance (Practical discussion on the dos and don'ts of interacting with HCPs in Latin America)	Marcelo Nogueira, Novartis (São Paulo)
2:05 – 2:25	Break	
2:25 – 4:45	Interactive Team Case Study	Cory LaBarge, Grünenthal (Panama) Sergio Alberto Pinto, Johnson & Johnson (São Paulo)
4:45 – 5:15	Conclusion of Program – Closing remarks & awarding of program certificates	

- Conclusion of Program -